Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Arch Osteoporos ; 14(1): 72, 2019 06 28.
Article in English | MEDLINE | ID: mdl-31254130

ABSTRACT

This analysis was performed in Zambian children who had a high prevalence of hypervitaminosis A, defined as > 1.0 µmol retinol/g liver. Bone parameters included markers of bone formation (P1NP), bone resorption (CTX), parathyroid hormone, calcium, vitamin A, and vitamin D. Low dietary vitamin A intake increased P1NP. PURPOSE: Vitamin A (VA) interacts with bone health, but mechanisms require clarification. In countries where multiple interventions exist to eradicate VA deficiency, some groups are consuming excessive VA. Bone metabolism and inflammatory parameters were measured in Zambian children who had high prevalence of hypervitaminosis A determined by 13C-retinol isotope dilution. METHODS: Children (n = 143), 5 to 7 years, were recruited into a placebo-controlled biofortified orange maize feeding study for 90 days. Bone turnover (P1NP and CTX) and inflammatory (C-reactive protein (CRP) and alpha-1-acid glycoprotein) biomarkers were measured in fasting blood samples before and/or after intervention with the following: (1) VA at the recommended dietary allowance (400 µg retinol activity equivalents/day (as retinyl palmitate)), (2) maize enhanced with the provitamin A carotenoid ß-carotene (2.86 mg/day), or (3) a placebo. Parathyroid hormone, calcium, and 25(OH)-vitamin D were measured at end line. RESULTS: Bone formation, as measured by P1NP, increased (P < 0.0001) in the placebo group who consumed low preformed VA during the intervention. Bone resorption, measured by CTX, was not affected. P1NP and CTX were negatively associated with inflammation, most strongly with CRP. Serum calcium did not differ among groups and was low (7.29 ± 0.87 µg/dL). Serum 25(OH) D did not differ among groups (54.5 ± 15 nmol/L), with 91% < 75 nmol/L and 38% < 50 nmol/L. CONCLUSIONS: Reduction of dietary preformed VA in Zambian children for 4 months improved bone formation. Chronic consumption of preformed VA caused hypervitaminosis A and may impair bone formation. In children, this could be associated with failure to accrue optimal peak bone mass. TRIAL REGISTRATION: The NIH Clinical Trial registry number is NCT01814891; https://clinicaltrials.gov/ct2/show/NCT01814891 .


Subject(s)
Bone Remodeling , Hypervitaminosis A/diet therapy , Osteogenesis , Vitamin A/adverse effects , Biomarkers/blood , C-Reactive Protein , Child , Child, Preschool , Diet , Diterpenes , Female , Humans , Liver , Male , Nutritional Status , Parathyroid Hormone/blood , Provitamins , Retinyl Esters , Vitamin A/analogs & derivatives , Vitamins , Zea mays
2.
Osteoporos Int ; 17(5): 704-15, 2006.
Article in English | MEDLINE | ID: mdl-16491322

ABSTRACT

INTRODUCTION: 2-Methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 (2MD) is a new analog of 1alpha,25-dihydroxyvitamin D3 (1,25-(OH)2D3) that has unique properties (distinct from 1alpha,25-dihydroxyvitamin D3) in stimulating osteoblasts to form bone in culture. This analog has now been extensively tested in aged ovariectomized female rats maintained on a diet adequate in calcium and phosphorus. METHODS: Retired female rats obtained from Sprague-Dawley were ovariectomized, and were either dosed with vehicle or 2MD at 5-7 ng/kg body weight each day. RESULTS: A marked increase in total bone mass resulted during the 28-week study. This increase in bone mass resulted from an increase in both cortical and trabecular bone, with increases to the order of 25% in the cancellous bone. Histomorphometry revealed that 2MD increased bone mass primarily by increasing bone formation. It also revealed little or no effect on bone resorption. The resulting bone is of high quality revealed by histology and biomechanical testing. CONCLUSION: Throughout the study, serum calcium remained within the normal range and thus 2MD shows great promise for the treatment of bone diseases characterized by bone loss, including osteoporosis.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Resorption/drug therapy , Calcitriol/analogs & derivatives , Osteogenesis/drug effects , Osteoporosis/drug therapy , Anabolic Agents/therapeutic use , Analysis of Variance , Animals , Bone Density/drug effects , Calcitriol/therapeutic use , Calcium/blood , Female , Rats , Rats, Sprague-Dawley
3.
Osteoporos Int ; 17(5): 768-74, 2006.
Article in English | MEDLINE | ID: mdl-16435075

ABSTRACT

INTRODUCTION: Changes in bone mineral density are used to monitor osteoporosis therapy. To determine whether a change in bone mass is clinically significant, the precision of bone mineral density measurements must be known. METHODS: We therefore measured the impact of vertebral body exclusion on dual energy X-ray absorptiometry (DXA) precision. At one university and one Veterans Affairs DXA center, three radiology technologists each scanned 30 participants twice, with repositioning between scans, to estimate DXA precision. Three International Society for Clinical Densitometry-certified physicians reviewed all lumbar spinal scans to note the presence of focal structural defects. We calculated precision for subsets of vertebrae, and for virtual samples of patients with and without physician-identified vertebral focal structural defects. We graphed the reciprocal of least significant change versus bone area to determine the dependence of precision on interpreted scan area. RESULTS: Within each sample, greater interpretable bone area improved precision. The contribution of interpreted bone area to precision differed among the samples, ranging from 57 to 94%. Greater population bone mineral density heterogeneity and presence of focal structural defects each decreased precision. CONCLUSION: All bone densitometry centers must determine precision using a sample representative of their served populations. Failure to do so may lead to incorrect determination of least significant change. Population heterogeneity, vertebral body exclusion and presence of focal structural defects each decreases precision.


Subject(s)
Absorptiometry, Photon/standards , Lumbar Vertebrae/diagnostic imaging , Osteoporosis/diagnostic imaging , Absorptiometry, Photon/methods , Aged , Bone Density , Female , Humans , Lumbar Vertebrae/physiopathology , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
4.
Am J Clin Nutr ; 72(6): 1523-8, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11101481

ABSTRACT

BACKGROUND: Subclinical vitamin K insufficiency, manifested by under-gamma-carboxylation of the bone matrix protein osteocalcin, may be common. OBJECTIVE: Our objective was to delineate the prevalence of submaximal gamma-carboxylation as assessed by response to phylloquinone supplementation and to evaluate the effect of this intervention on skeletal turnover in healthy North American adults. DESIGN: Healthy subjects (n = 219), approximately equally distributed by sex and age (18-30 y and >/=65 y), received daily phylloquinone (1000 microg) or placebo for 2 wk. Serum undercarboxylated osteocalcin (ucOC) and total osteocalcin, N:-telopeptides of type I collagen (NTx), bone-specific alkaline phosphatase (BSAP), and phylloquinone concentrations were measured at baseline and after weeks 1 and 2. RESULTS: At baseline, the mean serum phylloquinone concentration was lower in the young than in the old group; there was no effect of sex. Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P: < 0.0001) but did not differ significantly by age in women. After supplementation, serum phylloquinone concentration increased approximately 10-fold (P: < 0.0001) at week 1 (from 0.93 +/- 0.08 to 8.86 +/- 0.70 nmol/L, x+/- SEM); this was sustained through week 2. Among all supplemented groups, mean %ucOC decreased from 7.6% to 3. 4% without significant differences by age or sex; 102 of 112 subjects had a >1% decrease. Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration. CONCLUSIONS: Usual dietary practices in this population did not provide adequate vitamin K for maximal osteocalcin carboxylation. Phylloquinone supplementation reduced serum osteocalcin concentration but did not alter other markers of serum bone turnover.


Subject(s)
Aging/metabolism , Antifibrinolytic Agents/pharmacology , Osteocalcin/blood , Osteocalcin/drug effects , Vitamin K 1/pharmacology , Adolescent , Adult , Aged , Analysis of Variance , Bone and Bones/drug effects , Bone and Bones/metabolism , Dietary Supplements , Female , Humans , Male , Single-Blind Method , Vitamin K 1/blood
5.
Exp Gerontol ; 35(9-10): 1131-49, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11113597

ABSTRACT

Dietary restriction (DR) retards aging and extends the maximum lifespan of laboratory mice and rats. To determine whether DR has similar actions in a primate species, we initiated a study in 1989 to investigate the effects of a 30% DR in 30 adult male rhesus monkeys. In 1994, an additional 30 females and 16 males were added to the study. Although the animals are still middle-aged, a few differences have developed between the control and DR animals suggesting that DR may induce physiologic changes in the rhesus monkey similar to those observed in rodents. Fasting basal insulin and glucose concentrations are lower in DR compared to control animals while insulin sensitivity is higher in the restricted animals. DR has also altered circulating LDL in a manner that may inhibit atherogenesis. These results suggest that DR may be slowing some age-related physiologic changes. In addition to measures of glucose and lipid metabolism, the animals are evaluated annually for body composition, energy expenditure, physical activity, hematologic indices, and blood or urinary hormone concentrations. In the next few years, the first animals will reach the average lifespan ( approximately 26 years) of captive rhesus monkeys and it will become possible to determine if DR retards the aging process and extends the lifespan in a primate species.


Subject(s)
Aging/physiology , Diet , Animals , Behavior, Animal , Blood Glucose/metabolism , Body Composition , Body Weight , Bone Density , Dehydroepiandrosterone/blood , Energy Metabolism , Female , Hydrocortisone/blood , Insulin/blood , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor I/metabolism , Leptin/blood , Lipids/blood , Macaca mulatta , Male , Melatonin/urine , Physical Exertion , Time Factors , Triiodothyronine/blood
6.
Bone ; 26(1): 55-62, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10617157

ABSTRACT

To characterize the role of interleukin-6 (IL-6) in estrogen (E2)-depletion bone loss, we utilized a nonhuman primate model of human skeletal physiology. Adult female rhesus monkeys were sham-operated (S; n = 5), ovariectomized (ovx; n = 10), or ovx followed by E2 replacement (ovx + E2; n = 10) and evaluated for the indicated parameters at 0, 3, 6, and 9 months post-ovx. Lumbar spine bone mineral density (BMD) decreased by 3 months and continued to decline through 9 months in the ovx, but not in the ovx + E2 or S groups. Middle and distal radius BMD was decreased at 9 months in the ovx, but not in the ovx + E2 or S groups. The S group had marked fluctuations in bone remodeling parameters, and cytokine levels in S animals were consistent with menstrual cycling, and therefore only those values in the ovx and ovx + E2 groups are reported. Serum osteocalcin and skeletal-specific alkaline phosphatase were elevated in the ovx group compared with the ovx + E2 group. There was no difference in serum or bone marrow plasma IL-6 levels between the ovx and ovx + E2 groups. Similarly, there was no difference in basal or phorbol ester-stimulated IL-6 levels of peripheral blood mononuclear cell or bone marrow cell culture supernatants between groups. There was no difference in serum or bone marrow soluble IL-6 receptor between groups. However, the bone marrow plasma soluble IL-6 receptor levels were transiently increased from baseline at 3 months in the ovx but not in the ovx + E2 group. In summary, there was no bone loss in the ovx + E2 group, although the serum and bone marrow IL-6 levels were similar to those of the ovx group. These data suggest that modulation of IL-6 is not the key mechanism through which estrogen deprivation mediates bone loss in rhesus monkeys.


Subject(s)
Bone Diseases, Metabolic/physiopathology , Interleukin-6/physiology , Animals , Biomarkers , Bone Density , Bone Diseases, Metabolic/metabolism , Bone Remodeling , Dinoprostone/metabolism , Female , Humans , Macaca mulatta , Ovariectomy
7.
Ann Pharmacother ; 34(12): 1380-4, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11144692

ABSTRACT

OBJECTIVE: To determine whether glucocorticoid-induced osteoporosis in male veterans was managed in accordance with American College of Rheumatology (ACR) guidelines. These guidelines recommend bone mineral density (BMD) determination at the initiation of long-term therapy with prednisone > or =7.5 mg/d, provision of hormone replacement therapy as needed, calcium and vitamin D supplementation as necessary, and antiresorptive therapy for low BMD. DESIGN: Patients receiving prednisone > or =7.5 mg/d throughout a predefined six-month period were identified through a hospital pharmacy database. Electronic and paper chart review was carried out to determine whether BMD measurement by dual-energy X-ray absorptiometry had been performed. Supplemental calcium and vitamin D intake was assessed for each patient. In addition, pharmacy records were reviewed to determine whether antiresorptive therapy was prescribed for patients with low BMD. SETTING: The Wm. S. Middleton Veterans Affairs Medical Center, Madison, WI. RESULTS: Seventy-two men met study criteria. They had been receiving oral prednisone treatment for a median of 30 months (range 6-74); mean daily dosage during the six-month study period was 12.5 mg (range 7.5-37.5). Extensive record review revealed that only six patients (8%) received recommended calcium and vitamin D, and only 43 (60%) had a BMD determination. Of those 43 men, 32 had T-scores below -1, therefore meeting ACR criteria for recommended antiresorptive therapy. However, only 12 of these 32 patients were prescribed antiresorptive therapy. Although this study was not designed to evaluate differences among clinics, there appeared to be better adherence to ACR guidelines for patients cared for in a rheumatology specialty clinic than in other clinics at the institution. CONCLUSIONS: Adherence to ACR guidelines for management of glucocorticoid-induced osteoporosis was poor. Efforts to improve the prevention and management of glucocorticoid-induced osteoporosis in male veterans are warranted.


Subject(s)
Glucocorticoids/adverse effects , Osteoporosis/drug therapy , Prednisone/adverse effects , Veterans , Adult , Aged , Bone Density , Calcium/therapeutic use , Dietary Supplements , Disease Management , Gonadal Steroid Hormones/therapeutic use , Hospitals, Veterans , Humans , Male , Middle Aged , Osteoporosis/chemically induced , Osteoporosis/physiopathology , Testosterone/therapeutic use , Vitamins/therapeutic use
8.
J Nutr ; 129(6): 1201-3, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10356087

ABSTRACT

Phylloquinone (K) absorption was assessed in 22- to 30-y-old human subjects consuming a standard test meal [402 kcal (1682 kJ), 27% energy from fat]. The absorption of phylloquinone, measured over a 9-h period as the area under the curve (AUC), was higher (P < 0.01) after the consumption of a 500- microgram phylloquinone tablet [27.55 +/- 10.08 nmol/(L. h), n = 8] than after the ingestion of 495 microgram phylloquinone as 150 g of raw spinach [4.79 +/- 1.11 nmol/(L. h), n = 3]. Less phylloquinone (P < 0.05) was absorbed from 50 g of spinach (AUC = 2.49 +/- 1.11 nmol/(L. h) than from 150 g of spinach. Absorption of phylloquinone from fresh spinach (165 microgram K), fresh broccoli (184 microgram K) and fresh romaine lettuce (179 microgram K) did not differ. There was no difference in phylloquinone absorption from fresh or cooked broccoli or from fresh romaine lettuce consumed with a meal containing 30 or 45% energy as fat.


Subject(s)
Vegetables , Vitamin K 1/pharmacokinetics , Absorption , Adult , Biological Availability , Brassica , Humans , Lactuca , Spinacia oleracea , Tablets , Vitamin K 1/administration & dosage , Vitamin K 1/pharmacology
9.
J Nutr ; 125(7): 1812-21, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7616295

ABSTRACT

Although the abundance of vitamin K-dependent proteins in bone suggests an important function, the precise role of vitamin K in skeletal health remains to be determined. Serum concentrations of vitamin K are reportedly reduced in older individuals and persons with osteoporotic fracture. Whether this is causally related to vitamin K insufficiency or simply reflects inadequate nutritional status is unclear. Circulating levels of undercarboxylated osteocalcin may be a sensitive marker of vitamin K inadequacy and have been reported to be increased in both postmenopausal women and individuals who sustained hip fracture. It is also possible that vitamin K indirectly affects the skeleton via control of renal calcium excretion. The effect of vitamin K antagonists (oral anticoagulants) on both renal calcium excretion and bone density is controversial. Thus, many of the reports implicating a role for vitamin K insufficiency in the development of osteoporosis are conflicting. This review summarizes current knowledge regarding a possible role of vitamin K insufficiency in the pathogenesis of osteoporosis.


Subject(s)
Extracellular Matrix Proteins , Nutritional Physiological Phenomena , Osteoporosis/etiology , Vitamin K/physiology , Aged , Amino Acid Sequence , Calcium-Binding Proteins/chemistry , Female , Humans , Middle Aged , Molecular Sequence Data , Osteocalcin/chemistry , Osteoporosis/physiopathology , Vitamin K Deficiency/physiopathology , Matrix Gla Protein
10.
Lymphokine Cytokine Res ; 13(4): 221-6, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7999921

ABSTRACT

The role of interleukin-6 in the bone microenvironment is controversial. We studied the effect of recombinant human interleukin-6 (rhIL-6) administration on bone metabolism in 10 adult female rhesus monkeys (age 12-27 years). Monkeys received rhIL-6 (15 micrograms/kg/day) daily by subcutaneous injection for 28 days. Serum alkaline phosphatase, osteocalcin, and 24 h urinary calcium excretion were determined before, during (at weeks 2 and 4), and after (at week 6) treatment. Transilial biopsies (right and left) were obtained before treatment was initiated and just after the final (28th) dose at week 4. The serum alkaline phosphatase significantly increased at 2 and 4 weeks of rhIL-6 administration. Osteocalcin and urinary calcium excretion significantly decreased at week 2. Upon treatment with rhIL-6 significant reductions in OS/BS and Ob.S/BS were observed without changes in other static histomorphometry parameters. The reductions in urinary calcium excretion, serum osteocalcin, and the static bone parameters are consistent with an IL-6 induced reduction in bone formation or turnover. Whether this pharmacologic effect is relevant at the physiologic level remains to be determined.


Subject(s)
Bone and Bones/metabolism , Interleukin-6/pharmacology , Alkaline Phosphatase/blood , Animals , Biopsy , Bone and Bones/cytology , Bone and Bones/drug effects , Calcium/urine , Female , Humans , Injections, Subcutaneous , Interleukin-6/administration & dosage , Macaca mulatta , Menopause , Osteocalcin/blood , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Time Factors , gamma-Glutamyltransferase/blood
11.
Am J Gastroenterol ; 74(6): 522-4, 1980 Dec.
Article in English | MEDLINE | ID: mdl-7211816

ABSTRACT

An immunocompetent adult male was found to have obstructive lymphoid hyperplasia of the terminal ileum. The lesion persisted without malignant change for at least one year. Following surgical resection he had symptomatic relief.


Subject(s)
Ileal Diseases/etiology , Ileum/pathology , Intestinal Obstruction/etiology , Lymph Nodes/pathology , Humans , Hyperplasia , Ileal Diseases/immunology , Ileal Diseases/surgery , Ileum/surgery , Immunocompetence , Intestinal Obstruction/immunology , Intestinal Obstruction/surgery , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...